VC: Ablynx lands $50M in VC

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Ablynx
Ghent, Belgium

$50M
Third

KBC

Ablynx will now be able to fund operations through to at least mid-2008, allowing the company to further develop its product pipeline based on its Nanobody technology and to rapidly increase its head count.

Intranasal Therapeutics (ITI)
Lexington, KT

$39.1M
First

SV Life Sciences

The funding will be used to launch a hydromorphone nasal spray for acute pain that is currently in Phase II/III testing. press release

TolerRx
Cambridge, MA

$35.6M
Unknown

FrontPoint Partners

The funds will support the clinical development of TolerRx's lead product, TRX4, an anti-CD3 monoclonal antibody in development for Type 1 diabetes and psoriasis.

Kemia
San Diego, CA

$31M
Third

Aberdare Ventures

The company plans to use the proceeds to advance its lead clinical compound, KC706, through initial Phase II clinical trials.

Thiakis
United Kingdom

$19M
First

Novo A/S and Advent Venture Partners

The company is focused on the development of peptide hormones for the treatment of obesity.

Cempra Pharmaceuticals
Morrisville, NC

$14M
First

Intersouth Partners and I. Wistar Morris III

Cempra will advance its pipeline of antibiotics.

LipoScience
Raleigh, NC

$13M
Sixth

Camden Partners, GE Capital Equity Investments, INVESCO Private Capital, Pappas Ventures, Sightline Partners, Three Arch Partners, and Varian

The funding will allow LipoSciences to invest in the deployment of the in-vitro diagnostic system.

Accera
Broomfield, CO

$7.5M
Round

Inventages Venture Capital

Most of the money will go to two mid-stage trials.

4-Antibody
Switzerland

$6M
First

Biomedinvest, Grazia Equity, Life Science Partners and Mulligan Biocapital

4-Antibody will move forward pursue internal and collaborative development projects for fully human antibodies.